PLSH — Panacea Life Sciences Holdings Share Price
0.000.00%
Last trade - 00:00- $2.91m
- $14.95m
- $2.38m
- 29
- 45
- 19
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -192.25% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.35 | 2.07 | 2.06 | 1.63 | 2.38 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Panacea Life Sciences Holdings, Inc. is a holding company organized as a plant-based natural health ingredient and product company. It specializes in the development, manufacturing, research, and distribution of products with natural health and wellness market segment for both humans and animals. The Company’s subsidiary, Panacea Life Sciences, Inc. (PLS) is engaged in the production, distribution, research, and manufacturing of nutraceuticals, cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products. The Company also offers natural remedies within its branded product lines for every aspect of life, including PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure, and PANA Life. It also operates 51,000 square foot current good manufacturing practice (cGMP) facility located in Golden, Colorado. The Company, through Panacea Life Sciences Holdings, Inc., manages six retail locations and a distribution center situated in the Tampa, Florida area.
Directors
- Lawrence Wert CEO (64)
- Timothy Ryan EVP
- James Sposato CIO
- Leslie Buttorff DRC
- Jim Mish DRC
- Janice Nerger DRC
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 18th, 2008
- Public Since
- November 24th, 2015
- No. of Shareholders
- 190
- No. of Employees
- 40
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 17,645,352
Upcoming Events for PLSH
Q3 2024 Panacea Life Sciences Holdings Inc Earnings Release
Similar to PLSH
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Panacea Life Sciences Holdings share price?
As of Today at 22:34 UTC, shares in Panacea Life Sciences Holdings are trading at $0.17. This share price information is delayed by 15 minutes.
How has the Panacea Life Sciences Holdings share price performed this year?
Shares in Panacea Life Sciences Holdings last closed at $0.17 and the price had moved by -66.86% over the past 365 days. In terms of relative price strength the Panacea Life Sciences Holdings share price has underperformed the S&P500 Index by -72.19% over the past year.
What are the analyst and broker recommendations for Panacea Life Sciences Holdings?
There is no consensus recommendation for this security.
What is the Panacea Life Sciences Holdings dividend yield?
Panacea Life Sciences Holdings does not currently pay a dividend.
Does Panacea Life Sciences Holdings pay a dividend?
Panacea Life Sciences Holdings does not currently pay a dividend.
When does Panacea Life Sciences Holdings next pay dividends?
Panacea Life Sciences Holdings does not currently pay a dividend.
How do I buy Panacea Life Sciences Holdings shares?
To buy shares in Panacea Life Sciences Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Panacea Life Sciences Holdings?
As of the previous close price of $0.17, shares in Panacea Life Sciences Holdings had a market capitalisation of $2.98m.
Where are Panacea Life Sciences Holdings shares listed?
Here are the trading details for Panacea Life Sciences Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PLSH
What kind of share is Panacea Life Sciences Holdings?
Based on an overall assessment of its quality, value and momentum Panacea Life Sciences Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Panacea Life Sciences Holdings share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Panacea Life Sciences Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Panacea Life Sciences Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -23.48%.
As of the last closing price of $0.17, shares in Panacea Life Sciences Holdings were trading -37.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Panacea Life Sciences Holdings PE Ratio?
The Panacea Life Sciences Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Panacea Life Sciences Holdings?
Panacea Life Sciences Holdings' management team is headed by:
- Lawrence Wert - CEO
- Timothy Ryan - EVP
- James Sposato - CIO
- Leslie Buttorff - DRC
- Jim Mish - DRC
- Janice Nerger - DRC